evokepharma.com (EVOK): Net earnings per share for the last 12 months

Public company logo of Evoke Pharma, Inc. (EVOK)

Evoke Pharma, Inc. (EVOK) relies on a stable staff of biochemists and gastroenterology experts. The change in the rolling annual EPS on GURU.Markets demonstrates profit dynamics, where the value has stabilized at -2.39. Business revenues are based on the sale of the Gimoti nasal spray. The product is in demand among gastroenterologists and patients with diabetic gastroparesis seeking an effective alternative to traditional tablets.

EVOK (evokepharma.com) Net earnings per one share for the last twelve months history from 07/04/2022 to 12/27/2025

Analytical breakdowns and data insights for company Evoke Pharma Inc (EVOK)

- stock price and consensus target price:
Analysis of all company metrics:Evoke Pharma Inc (EVOK)
Mass-produced product of Evoke Pharma, Inc

This metric is calculated as the ratio of annual net income to the weighted average number of common shares. The metric determines the actual beneficiary income, eliminating distortions from share issuances or share buybacks. For Evoke Pharma, Inc. (EVOK), reliance on contract manufacturing organizations (CMOs) directly impacts margins and the bottom line. By analyzing the TTM fundamental earnings per share trend on the GURU.Markets platform, an investor can identify hidden debt risks behind apparent stability.